

---

# Global Vaccine and Immunization Research Forum

March 4 - 6, 2014

Hyatt Regency Bethesda, Maryland, USA



## Overview and Goals

Joachim Hombach, WHO

# From "Montreux" to GVRF to GVIRF

---



- WHO Montreux meetings (1990'ties)
  - Progress in vaccine R&D
- WHO Global Vaccine Research Fora (2000- 2011)
  - Progress in vaccine R&D and research needs of the global community
- WHO/NIAID/BMGF Global Vaccine & Immunization Research Forum (2014 -)
  - The complete spectrum of research and innovation in relation to vaccines & immunization with reference to the Global Vaccine Action Plan (GVAP).

# Global Vaccine and Immunization Research Forum

March 4 - 6, 2014

Hyatt Regency Bethesda, Maryland, USA



- **Convened jointly by BMGF, NIAID and WHO**
- **Participation: ~200 individuals affiliated with private and public organizations from developed and developing countries**
- **GVIRF agenda developed by SoC and secretariat to:**
  - ***track GVAP R&D agenda progress within the M&E and Accountability Framework;***
  - ***identify opportunities and challenges for the vaccine and immunization R&D community;***
  - ***build and strengthen a research community networking opportunity; and***
  - ***facilitate inclusion of other stakeholders in the development and implementation of an R&D agenda.***

# R&D Goals and Indicators of the GVAP



## Strategic Objective 6: Country, Regional and Global R&D Innovations Maximize the Benefits of Immunization

Indicator	Target	Progress
(6.1) Progress towards the development of HIV, TB and malaria vaccines	Proof of concept for a vaccine that shows >75% efficacy	Tracking of clinical trial databases and narrative qualitative report
(6.2) Progress towards a universal influenza vaccine	At least one vaccine providing broad spectrum protection against Influenza A is licensed.	Tracking of clinical trial databases and narrative qualitative report
(6.3) Progress towards institutional and technical capacity to carry out vaccine clinical trials	Every region has a solid base of competent countries	Review of clinical trials registry platform

# R&D Goals and Indicators of the GVAP



## Goal 4: Develop and Introduce New and Improved Vaccines and Technologies

Indicator	Target	Progress
(4.1) Licensure and launch of vaccine(s) against one or more major, currently non-vaccine preventable disease	One or more vaccines licensed and launched by a functional NRA	NRA surveys and qualitative reports on incremental progress
(4.2) Licensure and launch of at least one platform delivery technology	One or more delivery technology licensed and launched by a functional NRA	NRA surveys and qualitative reports on incremental progress

# Global Vaccine and Immunization Research Forum

March 4 - 6, 2014



Hyatt Regency Bethesda, Maryland, USA

- **Day 1 Theme: Vaccine Development**
- **Keynote: A.S. Fauci (NIAID)**
- **Plenary Sessions:**
  - *Develop new & improved vaccines (S06.1)*
  - *Regulatory & public health challenges for vaccines inducing modest efficacy (G4.1)*
- **Workshops:**
  - *Towards the development of a universal influenza vaccine (S06.2)*
  - *Preferred product characteristics (PPC) as a way to guide development of products (G4.1)*
  - *Vaccines against Neglected Infectious Diseases (G4.1)*
- **Plenary Session:**
  - *Developing next generation vaccines: defining the improvements needed and evaluating their potential (G4.1)*

# Global Vaccine and Immunization Research Forum

March 4 - 6, 2014



Hyatt Regency Bethesda, Maryland, USA

- **Day 2 Theme: Implementation Research**
- **Keynote: M. Chan (WHO)**
- **Plenary Session:**
  - ***Research for universal coverage and immunization in the post-MDG poverty reduction agenda (G5, S02, S03)***
- **Workshops:**
  - ***How to optimize immunization coverage? Case study of measles-rubella vaccination (G2.2, G2.3, S04.4)***
  - ***Research capacity strengthening to foster implementation research in developing countries (S06.3)***
  - ***Innovation in vaccine delivery and presentation: how can technological advances increase program performance?(G4.2)***
- **Plenary Sessions:**
  - ***Research to improve monitoring and evaluation of immunization programmes (S04)***
  - ***Protection of pregnant women, neonates and infants by maternal immunization (G4.1)***



# Global Vaccine and Immunization Research Forum

March 4 - 6, 2014



Hyatt Regency Bethesda, Maryland, USA

- **Day 3 Theme: Innovation, discovery and regulation**
- **Keynote: T. Mundel (BMGF)**
- **Plenary Session:**
  - ***Innovative vaccine research: the point of view of pharmaceutical and biotechnology companies (G4)***
- **Workshops:**
  - ***Contributions of regulatory science to vaccine access (S05, G4)***
  - ***How can recent technological advances in vaccinomics and systems vaccinology accelerate next-generation vaccine development? (G4.1)***
- **Plenary Session:**
  - ***Closing comments***